Disc Medicine, Inc. (NASDAQ:IRON) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. trimmed its position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 29.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 220,014 shares of the company's stock after selling 92,035 shares during the period. Victory Capital Management Inc. owned 0.74% of Disc Medicine worth $10,811,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Atlas Venture Life Science Advisors LLC boosted its holdings in Disc Medicine by 9.7% in the second quarter. Atlas Venture Life Science Advisors LLC now owns 2,509,456 shares of the company's stock valued at $113,101,000 after acquiring an additional 222,223 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its stake in Disc Medicine by 123.5% in the second quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company's stock valued at $79,090,000 after buying an additional 969,834 shares during the period. Deerfield Management Company L.P. Series C grew its position in shares of Disc Medicine by 53.8% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company's stock worth $46,119,000 after buying an additional 357,730 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Disc Medicine by 59.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company's stock worth $58,788,000 after acquiring an additional 353,382 shares in the last quarter. Finally, Logos Global Management LP bought a new stake in Disc Medicine in the second quarter valued at $41,690,000. Institutional investors own 83.70% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Raymond James raised Disc Medicine from an "outperform" rating to a "strong-buy" rating and boosted their target price for the company from $66.00 to $110.00 in a research report on Monday, November 4th. Cantor Fitzgerald restated an "overweight" rating and issued a $85.00 target price on shares of Disc Medicine in a report on Tuesday, October 15th. Wells Fargo & Company assumed coverage on Disc Medicine in a research note on Thursday, August 22nd. They set an "overweight" rating and a $75.00 price objective on the stock. Scotiabank raised their price target on shares of Disc Medicine from $62.00 to $70.00 and gave the company a "sector outperform" rating in a research report on Tuesday, November 5th. Finally, Morgan Stanley raised shares of Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 price objective for the company in a research report on Tuesday, November 5th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Disc Medicine currently has an average rating of "Buy" and a consensus target price of $85.80.

Disc Medicine Stock Performance

Shares of Disc Medicine stock traded up $0.96 during midday trading on Thursday, hitting $63.51. The company had a trading volume of 362,394 shares, compared to its average volume of 354,425. The company has a 50 day moving average of $51.79 and a 200 day moving average of $45.73. Disc Medicine, Inc. has a 52-week low of $25.60 and a 52-week high of $77.60.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.15. On average, equities research analysts predict that Disc Medicine, Inc. will post -4.05 earnings per share for the current fiscal year.

Insider Transactions at Disc Medicine

In other Disc Medicine news, insider William Jacob Savage sold 9,158 shares of the company's stock in a transaction on Friday, November 15th. The stock was sold at an average price of $59.64, for a total value of $546,183.12. Following the transaction, the insider now owns 40,405 shares of the company's stock, valued at $2,409,754.20. This represents a 18.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director William Richard White sold 7,136 shares of Disc Medicine stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 16,696 shares of company stock worth $984,058. Corporate insiders own 4.24% of the company's stock.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.